Shingrix for Herpes Zoster: A Review Shingrix for Herpes Zoster: A Review

This brief primer reviews the pathophysiology of herpes zoster, and summarizes the results of the clinical trials of Shingrex, the newly approved recombinant vaccine for HZ prevention.Skin Therapy Letter
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Related Links:

For this month ’s issue of Annals, which focuses on vaccines, I’ve selected 3 article summaries from recent Allergy Watch that reviewed studies on various aspects of vaccines. The first reports data from the pivotal study showing the improved efficacy of the new recombinant subunit herpes zoster vaccine. The n ext review describes a report of a unique vaccine for cats that induces IgG blocking antibodies for Fel d 1. The last review shows discrepant results of pneumococcal titers from different labs.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Special Series Source Type: research
For this month's issue of Annals, which focuses on vaccines, there are 3 article summaries from recent AllergyWatch columns that reviewed studies on various aspects of vaccines. The first reports data from a pivotal study on the improved efficacy of the new recombinant subunit herpes zoster vaccine. The second review describes a report of a unique vaccine for cats that induces immunoglobulin G –blocking antibodies for Fel d 1. The third review reports discrepant results of pneumococcal titers from different laboratories.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Special Series Source Type: research
The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
This study examines the prevalence and patterns of influenza and herpes zoster vaccination among patients treated with mepolizumab in the real-world.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Publication date: Available online 2 August 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Laurie A. Housel, Bruce M. McClenathan
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Abstract The self-controlled tree-temporal scan statistic allows detection of potential vaccine- or drug-associated adverse events without pre-specifying the specific events or post-exposure risk intervals of concern. It thus opens a promising new avenue for safety studies. The method has been successfully used to evaluate the safety of two vaccines for adolescents and young adults, but its suitability to study vaccines for older adults had not been established. The current study applied the method to assess the safety of live attenuated herpes zoster vaccination during 2011-2017 in U.S. adults ≥ 60 years old, ...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
View Original Article Here: How Long Does Shingles Last In The Elderly? Shingles is a viral infection that follows a varicella-zoster infection, although it can take decades for symptoms of the secondary disease to emerge. The condition presents as a painful and blistering rash, but it is not life-threatening. According to the Center for Disease Control, there are nearly one million cases in the United States each year, and almost half of those cases are in older adults over age 60. Some people only see one instance of the illness, while others have recurring symptoms, but 30 percent of Americans will develop shingles at s...
Source: Shield My Senior - Category: Geriatrics Authors: Tags: Senior Safety Source Type: blogs
The herpes zoster subunit vaccine was effective and safe for adults aged 70 and older in a phase III manufacturer-sponsored clinical trial, which was reported online in the New England Journal of Medicine. The ZOE-70 study (Zoster Efficacy Study in Adults 70 years of Age or Older) assessed an...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
The herpes zoster vaccine should be administered earlier rather than later in order to achieve optimal immune response, but an additional booster shot for individuals 70 years or older is also advisable. This is according to a recent study published in the Journal of Infectious Diseases, which...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
Protection against shingles appeared to wane between the fifth and sixth years after patients with autoimmune diseases received the live herpes zoster vaccine, according to a large retrospective cohort study presented at the annual meeting of the American College of Rheumatology. In contrast,...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Clinical Trials | Dermatology | Herpes | Shingles (Herpes Zoster) Vaccine | Skin | Vaccines | Varicella-Zoster Virus Vaccine